Xaira Therapeutics, a new biotech startup focusing on AI-driven drug discovery, has successfully launched with over $1 billion in funding. The company, led by former Stanford president Marc Tessier-Lavigne, aims to leverage artificial intelligence to develop new therapeutic approaches that are difficult to achieve with conventional methods. The funding was jointly incubated by Arch Venture Partners and Foresite Labs, with significant contributions from other major investors. Tessier-Lavigne, who recently left Stanford following a controversial exit related to an investigation, is joined by high-profile figures in biotech, including Scott Gottlieb and Alex Gorsky, signaling a strong endorsement of Xaira's potential in the biotech industry. The company is built on foundational technology from David Baker.
AI for drug discovery draws a $1 billion launch—and a lot of hope. https://t.co/6j12nReIk4
AI tools are changing how pharmaceutical companies and public health institutions think about finding drugs to treat rare diseases. https://t.co/UhWk3DVcKB
⚕️💸⚕️Ex-Standford president’s Xaira Therapeutics secures $1B for AI drug discovery. https://t.co/13DFfMZf9N #XairaTherapeutics @ForesiteLabs @FPrimeCapital @NEA @sequoia @Lux_Capital @lightspeedvp @MenloVentures @TwoSigmaVC @parkerici @svangel #biotech #funding #news #US https://t.co/BY6oAke3MB
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs https://t.co/qPXeejJRYh
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs: https://t.co/7pFEzQ0e8F by TechCrunch #infosec #cybersecurity #technology #news
"If you asked an AI to generate a brand-new drug discovery biotech with a team of some of the biggest names in the biz for you, it couldn’t dream up one like Xaira Therapeutics." https://t.co/DtWqONmVGp
Former Stanford president Marc Tessier-Lavigne, who resigned following an investigation, has left the university for "biotech’s new AI mega-startup." https://t.co/OkKSwyUd6G https://t.co/sgfsC9dktL
Xaira launches with $1bn for AI drug discovery and development Company aims to leverage AI to ‘connect the world of biological targets and engineered molecules to the human experience of disease.’ @ForesiteCapital #AI #biotech #investment #drugdiscovery https://t.co/rHlSNFDILx https://t.co/uJdBBvqaq9
Big news: welcoming Xaira into portfolio with $1B in funding to pioneer new therapeutics by horizontally rebuilding the system w AI from scratch. + upcoming debut of another AI x BIO team building step-change capabilities in our arsenal of biological reasoning soon. https://t.co/xyTdS1pM0R
New #biotech Xaira Therapeutics emerges with $1bn in funding for its plan to apply #AI to #drugdiscovery in ways hard to achieve with conventional technologies https://t.co/y94BPrwCGL
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development | Business Wire https://t.co/qzrkkSkRRD
Xaira Therapeutics, which aims to use AI models to find new drugs to treat diseases, emerged from stealth with $1B in commitments from Sequoia and others (@mcbridesg / Bloomberg) https://t.co/XFlRE4Z2VZ 📫 Subscribe: https://t.co/OyWeKSRpIM https://t.co/fzA9b5oKzB
🚀 Mohamad Makhzoumi, @ScottGottliebMD, and the @NEA team are thrilled to partner with Xaira as they utilize AI tools to unlock opportunities in drug discovery. #AI #drugdiscovery https://t.co/E7JWdKE0DU
Former Stanford president Tessier Lavinge--ousted last summer in a scandal over fabricated drug data and coverup of same--has been tapped as CEO of Xaira, $1bn bet on AI-driven drug design! https://t.co/arscli8I5b
Ex-Stanford President Marc Tessier-Lavigne is now leading a $1 billion+ AI-focused biotech that includes a who's-who of biotech players https://t.co/K1jOVxiyaM
Congratulations to Xaira Therapeutics on the successful launch of its innovative biotech which leverages AI to better understand biological systems and develop new therapeutic approaches. We're entering an era of tremendous innovation and progress in the biotech space, and…
Thrilled to partner with the Xaira team on their mission to transform drug discovery & development with AI! https://t.co/fXfUIr8oev
Today we welcome @xaira_therapeutics to our portfolio, emerging from stealth with $1B in committed capital; jointly incubated by Arch Venture Partners / @rtnarch and @ForesiteLabs and led by Marc Tessier-Lavigne. Read more: https://t.co/Ge0Kfn0jS7
Exclusive Q&A with Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup, Xaira: https://t.co/wYMNUqwS3b
Part 3 of our coverage of the launch of AI drug startup of Xaira — a Q&A with CEO and ex-Stanford president Marc Tessier-Lavigne, talking to @AndrewE_Dunn + @RLCscienceboss about the company, his plans and his controversial exit from Stanford: https://t.co/rOmAduxLVs
Last year Marc Tessier-Lavigne stepped down from his post as president of Stanford. Now he is back as CEO of Xaira Therapeutics. @AndrewE_Dunn and I talked to him about AI, joining Xaira, the Stanford research integrity investigation and more for @endpts https://t.co/fGrP0Quzab
Delighted to share news of Xaira, built on foundational tech from David Baker and led by Marc Tessier-Lavigne. The Newco applies AI tools to unlock opportunities in drug discovery for aspects of biology not readily obtainable with conventional methods 1/n https://t.co/eGoyFBqr0c
In $1B+ bet on AI, biopharma heavyweights back Xaira Therapeutics to upend drug R&D. #AI $XBI https://t.co/Ua9hSj2m3z
Big welcome to Xaira - great to see the normalization of AI in drug discovery. A strong signal about the future. Great friends in @ScottGottliebMD, Alex Gorsky & @rtnarch at the helm. The next decade is going to be awesome in techbio! https://t.co/mqFpXyDRJY
In the biggest bet on AI for drug discovery and development yet, Xaira Therapeutics has raised over $1 billion from ARCH, Foresite and others, @AndrewE_Dunn and I exclusively report for @endpts. https://t.co/5qr1qWdEm5
🚨One of the biggest early VC bets in biotech EVER, Xaira is bringing together some of biotech's highest-profile names in a $1B+ bet on AI in drug development. A monster scoop from DunnCross(tm): https://t.co/AcYlAGt5gD
In biggest-ever bet on using AI to design drugs, biotech heavyweights launch Xaira with $1B+ in backing - massive from @AndrewE_Dunn and @RLCscienceboss https://t.co/Rxi9GMKIFy